Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026)

Prelude Therapeutics has disclosed FCF Margin across 3 years of filings, most recently posting 473.47% for Q1 2026.

• FCF Margin for Q1 2026 came in at 473.47%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 261.82% (changed N/A YoY), and the FY2025 annual result was 464.32%, up 100565.0% from the prior year.
• FCF Margin came in at 473.47% for Q1 2026 at Prelude Therapeutics, down from 409.91% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 409.91% in Q4 2025 to a low of 911.97% in Q3 2024.
• The 3-year median for FCF Margin is 473.47% (2026), against an average of 354.14%.
• Peak annual rise in FCF Margin reached 91099 bps in 2025, while the deepest fall reached 61789 bps in 2025.
• Prelude Therapeutics' FCF Margin stood at 501.08% in 2024, then jumped by 182 bps to 409.91% in 2025, then plunged by 216 bps to 473.47% in 2026.
• The last three FCF Margin figures came in at 473.47% (Q1 2026), 409.91% (Q4 2025), and 294.08% (Q3 2025), per Business Quant data.